News

« Previous 12345 Next »
Viewing Page 1 of 5 | Showing Results 1 - 10 of 43

Providence and Agonox Researchers Publish Groundbreaking Tumor Killing T-cell Research

July 13, 2018

Researchers at the Earle A. Chiles Research Institute, or EACRI, and Agonox, Inc. have published groundbreaking work concerning tumor-killing T cells which could greatly improve the immune response in cancer patients – leading to successful treatment of tumors.


Cancer Survivor Inspires 'Creating Hope' Donors; Event Breaks Record to Support Providence Research and Treatment

June 11, 2018

In a powerful speech to a packed house, Becky Roth spoke emotionally about the cancer that changed, but didn’t claim, her life. And, despite losing two leg bones used for her jaw reconstruction – and against all odds – she will run in the 2018 Providence Hood to Coast relay race to raise money for cancer research at Providence.

One study, multiple immunotherapy combinations for hormone-receptor-positive, HER2-negative breast cancer

April 23, 2018

Women with metastatic hormone-receptor-positive, HER2-negative breast cancer who have progressed after treatment with a CDK4/6 inhibitor may qualify for a newly opened immunotherapy study at Providence Cancer Institute.

Providence Cancer Institute expands outpatient services

March 09, 2018

From groundbreaking research to innovative treatments to compassionate care, everything we do at Providence Cancer Institute is for you, our patients. That’s why we’re expanding and consolidating outpatient cancer services on the 11th floor of our Robert W. Franz Cancer Center at Providence Portland Medical Center.

Adoptive T-cell transfer study opens for head and neck cancer patients

March 05, 2018

Adoptive T-cell transfer therapy is emerging as one of the most effective treatments to date for people with advanced melanoma. Now this treatment is available to patients with advanced or recurrent head and neck cancers through a clinical trial at Providence Cancer Institute.

New apalutamide study opens for prostate cancer

February 14, 2018

A new phase 3 study at Providence Cancer Institute will compare the effectiveness of three different treatment regimens in men with biochemically recurrent prostate cancer.

The Earle A. Chiles Research Institute Shines at SITC 2017 Annual Meeting

November 22, 2017

Walter J. Urba, M.D., Ph.D., Member, director and endowed chair, Earle A. Chiles Research Institute, Providence Cancer Institute The Earle A....

Providence Honors Early Advocate of Immunotherapy for Lifetime of Generosity and Service

October 03, 2017

In his lifetime and through his estate, the late Robert W. Franz gave close to $40 million to Providence Portland Medical Foundation. Providence Cancer Institute has been renamed in his honor.

Phase I research at Providence Cancer Institute

September 25, 2017
Phase I studies are the foundation for advancing cancer treatment with new agents and combinations of therapies. Providence Cancer Institute is often able to offer patients first-in-human clinical trials of novel cancer therapies through our own investigator-sponsored trials, and through collaborations with industry sponsors and other early-phase institutions around the country and worldwide.

Promising one-of-a-kind clinical trial adds immunotherapy to colorectal cancer treatment protocol

September 01, 2017

A first-of-its-kind clinical study may offer new hope to patients battling rectal cancer. The Phase 2 study, newly underway at Providence Cancer...

« Previous 12345 Next »
Viewing Page 1 of 5 | Showing Results 1 - 10 of 43